These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
451 related items for PubMed ID: 19047161
21. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Beck WT, Cirtain MC, Look AT, Ashmun RA. Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678 [Abstract] [Full Text] [Related]
22. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Kanakkanthara A, Northcote PT, Miller JH. Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309 [Abstract] [Full Text] [Related]
23. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB. Biochemistry; 2003 May 13; 42(18):5349-57. PubMed ID: 12731876 [Abstract] [Full Text] [Related]
24. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC, Guh JH. Biochem Pharmacol; 2007 Jun 30; 74(1):10-9. PubMed ID: 17475221 [Abstract] [Full Text] [Related]
25. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Chen JG, Yang CP, Cammer M, Horwitz SB. Cancer Res; 2003 Nov 15; 63(22):7891-9. PubMed ID: 14633718 [Abstract] [Full Text] [Related]
26. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Owellen RJ, Hartke CA, Dickerson RM, Hains FO. Cancer Res; 1976 Apr 15; 36(4):1499-502. PubMed ID: 1260766 [Abstract] [Full Text] [Related]
27. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line. Huffman KE, Corey DR. Biochemistry; 2005 Feb 22; 44(7):2253-61. PubMed ID: 15709737 [Abstract] [Full Text] [Related]
28. Molecular docking and pharmacogenomics of vinca alkaloids and their monomeric precursors, vindoline and catharanthine. Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla B, Plinkert PK, Krämer A, Gertsch J, Efferth T. Biochem Pharmacol; 2011 Mar 15; 81(6):723-35. PubMed ID: 21219884 [Abstract] [Full Text] [Related]
29. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. McCarroll JA, Gan PP, Liu M, Kavallaris M. Cancer Res; 2010 Jun 15; 70(12):4995-5003. PubMed ID: 20501838 [Abstract] [Full Text] [Related]
30. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC. Br J Cancer; 2000 Jul 15; 83(1):83-8. PubMed ID: 10883672 [Abstract] [Full Text] [Related]
31. Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Yoshida M, Matsui Y, Ikarashi Y, Usui T, Osada H, Wakasugi H. Anticancer Res; 2007 Jul 15; 27(2):729-36. PubMed ID: 17465195 [Abstract] [Full Text] [Related]
32. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW. Cancer Res; 2005 Oct 15; 65(20):9406-14. PubMed ID: 16230404 [Abstract] [Full Text] [Related]
33. Characterization of nuclear betaII-tubulin in tumor cells: a possible novel target for taxol. Xu K, Ludueña RF. Cell Motil Cytoskeleton; 2002 Sep 15; 53(1):39-52. PubMed ID: 12211114 [Abstract] [Full Text] [Related]
34. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M. Mol Cancer Ther; 2010 May 15; 9(5):1339-48. PubMed ID: 20442307 [Abstract] [Full Text] [Related]
35. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells. Isonishi S, Saitou M, Saitou M, Yasuda M, Tanaka T. Oncol Rep; 2007 Jul 15; 18(1):195-201. PubMed ID: 17549368 [Abstract] [Full Text] [Related]
36. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Fan T, Li R, Todd NW, Qiu Q, Fang HB, Wang H, Shen J, Zhao RY, Caraway NP, Katz RL, Stass SA, Jiang F. Cancer Res; 2007 Aug 15; 67(16):7901-6. PubMed ID: 17699796 [Abstract] [Full Text] [Related]
37. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M. J Natl Cancer Inst; 2006 Oct 04; 98(19):1363-74. PubMed ID: 17018783 [Abstract] [Full Text] [Related]
38. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Cancer Res; 1996 Jun 01; 56(11):2584-9. PubMed ID: 8653701 [Abstract] [Full Text] [Related]
39. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Cancer Res; 1976 Oct 01; 36(10):3798-802. PubMed ID: 954003 [Abstract] [Full Text] [Related]
40. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Ren XL, Xu YM, Bao W, Fu HJ, Wu CG, Zhao Y, Li ZK, Zhang J, Li SQ, Chen WQ, Wang T, Zhang R, Zhang LH, Qian GS, Chen SY, Jia LT, Yang AG. Cancer Lett; 2009 Aug 28; 281(2):134-43. PubMed ID: 19339104 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]